FDA approval of ropeginterferon alfa-2b-njft for the treatment of adult patients with polycythemia vera

On November 12, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved...

Genetic testing in the diagnosis and management of patients with BCR-ABL1-negative myeloproliferative neoplasms

Genetic and genomic testing are of increasing importance in the diagnosis and management...

Special populations in MPN: pediatric, adolescent, and young adults with MPN

Triple negative mutations i.e., the absence of driver mutations in JAK2, MPN and CALR are reported in many young patients...

Mutations in JAK2, CALR, and MPL and the effect on response to IFNα in MPN

Classical BCR-ABL1-negative myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV)...

The real-world survival benefit of ruxolitinib for myelofibrosis

The survival benefit of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib for patients with myelofibrosis (MF) is well established in...

Genetic testing in the diagnosis and management of patients with BCR-ABL1-negative myeloproliferative neoplasms

Genetic and genomic testing are of increasing importance in the diagnosis and management...

How did newer prognostic models change treatment algorithms in primary and secondary MF?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Laura Michaelis,...

Mutations in JAK2, CALR, and MPL and the effect on response to IFNα in MPN

Classical BCR-ABL1-negative myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV)...

Dual targeting of JAK2 and ERK1/2 enhances clone control and therapeutic efficacy in MPN

The activation of JAK2 signaling triggers the overproduction of mature blood cells of the myeloid lineage,...

Mutations in JAK2, CALR, and MPL and the effect on response to IFNα in MPN

Classical BCR-ABL1-negative myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV)...

Implications of clonal hematopoiesis of indeterminate potential (CHIP) for MPN

Clonal hematopoiesis of indeterminate potential (CHIP) is a state in which somatic mutations are found in the cells of...

TYK2 inhibition for CALR-mutated myeloproliferative neoplasms: a novel selective treatment approach

Genetic mutational drivers of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN)...